MergerJul 15, 2026, 09:07 AM
Nuvalent Acquired by GlaxoSmithKline for $124.00 per Share
AI Summary
Nuvalent, Inc. announced the completion of its acquisition by GlaxoSmithKline LLC, through its subsidiary Harmony Row Acquisition Co. The tender offer for all outstanding shares at $124.00 per share expired on July 14, 2026, with approximately 91.3% of shares validly tendered. Following the tender offer, the merger was completed on July 15, 2026, making Nuvalent a direct wholly-owned subsidiary of GlaxoSmithKline LLC. All outstanding shares, stock options, and restricted stock units were converted into the right to receive cash.
Key Highlights
- Nuvalent, Inc. was acquired by GlaxoSmithKline LLC.
- Tender offer price was $124.00 per share in cash.
- Offer expired on July 14, 2026, with 91.3% of shares tendered.
- A total of 72,518,967 shares were validly tendered.
- Merger completed on July 15, 2026, making Nuvalent a wholly-owned subsidiary.
- Outstanding shares, stock options, and RSUs converted to cash at the offer price.
Price Impact
More from NUVL